Cargando…
Vaccine response in people with multiple sclerosis treated with fumarates
People with multiple sclerosis (pwMS) have an increased risk of infection. As disease-modifying therapies (DMTs) and other treatments may interact with the immune system, there may be concerns about vaccine efficacy and safety. Therefore, it is important to evaluate possible interactions between DMT...
Autores principales: | Tremblay, Matthew A., Vukusic, Sandra, Shanmugasundaram, Mathura, Bozin, Ivan, Levin, Seth, Gocke, Anne, Wipfler, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483985/ https://www.ncbi.nlm.nih.gov/pubmed/37692293 http://dx.doi.org/10.1177/20552173231191170 |
Ejemplares similares
-
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023) -
Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
por: Lager, Brittney, et al.
Publicado: (2022) -
Diroximel fumarate for multiple sclerosis
Publicado: (2022) -
COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020) -
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)